Sionna Therapeutics announces first subjects dosed in Phase 1 trial on SION-451

Sionna Therapeutics (SION) announced that the first subjects have been dosed in a Phase 1 trial evaluating SION-451, a first-in-class nucleotide binding domain 1 stabilizer, in proprietary dual combinations with SION-2222, a transmembrane domain 1-directed CFTR corrector, and with SION-109, an intracellular loop 4-directed CFTR corrector.